JPMorgan lowered the firm’s price target on Biohaven (BHVN) to $15 from $47 and keeps an Overweight rating on the shares. The firm finds it “prudent” for Biohaven to undertake cost optimization efforts and restructure its business priorities following the complete response letter for Vyglxia. This should help refocus investor attention on the company’s key value drivers, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven call volume above normal and directionally bullish
- Biohaven price target lowered to $26 from $54 at Morgan Stanley
- Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges
- Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.
- Biohaven Ltd. Raises $200M in Public Offering